← FDA DRUG APPROVALS

FDA ANDA · ANDA077502

MYZILRA

Sponsor: PH HEALTH

APPLICATION
ANDA077502
TYPE
ANDA
ORIGINAL APPROVAL
2011-11-23
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

MYZILRADiscontinued
ETHINYL ESTRADIOL 0.03MG,0.04MG,0.03MG, LEVONORGESTREL 0.05MG,0.075MG,0.125MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 8 · standardAP
2017-08-09Labeling · Supplement 7 · standardAP
2014-08-04Manufacturing (CMC) · Supplement 4 · unknownAP
2011-11-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →